Mumbai: Oral antivirus, antibiotics, monoclonal antibodies and vitamins have no place in the latest Indian Covid management guidelines, which are installed on the UNI Ministry of Health website on Monday.
Antiviral remdesivir, which is given through Drip IV, is recommended for medium patients to very painful on oxygen support.
The use of rheumatoid arthritis rheumatoid drugs, Tocilizumab, continues for severe patients who do not improve with steroids.
The guideline came 10 days after the Head of the ICMR Dr.
Balram Bhargav stated that the new oral antivirus, Molnupiravir, had a “safety problem”.
Many doctors have different opinions.
“The general opinion among the medical communities is that this negligence is a mistake,” said an infectious disease specialist Dr.
Om Shrivastava, who is a member of the Maharashtra Task Force.
The task force guidelines allow Molnupiravir for patients aged more than 50 years and have at least two comorbidity and continuous fever for at least three days.
“Doctors must have discretionary rights to prescribe Molnupiravir because there are subset of patients who benefit it,” said a specialist of the infectious disease Dr.
Anita Mathew.
The ICMR guidelines state that patients with minor diseases need symptomatic treatment for fever and pain and, if needed, corticosteroidal nose spray (budesonide).
CT scans and expensive blood tests are only recommended for medium patients who are very seriously ill.
Last week, a group of 35 doctors wrote an open letter to Indian health authorities requested updated guidelines that clearly spell the government standing on new anti-virus and monoclonal antibodies so that “unreasonable drugs, testing and hospitalization” stopped.
Dr.
Satchit Balsari from Harvard School of Medicine and one of the signatories of the letter said, “Convincing to see that new guidelines are evidence-based antibiotics and eschew.
It is wise from the public health point of view that other drugs that have marginal benefits and are not available to most people Also not included.
I hope state institutions that have distributed drugs in bulk now leave practice.
“